Eli Lilly Stock: Cholesterol Drug Shows Breakthrough Results

Eli Lilly's experimental drug Lepodisiran has delivered impressive results in Phase 2 clinical trials, reducing a genetic risk factor for heart disease by nearly 94 percent. The drug targets Lipoprotein(a), or Lp(a), a risk factor affecting approximately 1.4 billion people worldwide, including 64 million Americans. Unlike LDL cholesterol, which can be managed through diet and statins, elevated Lp(a) levels currently have no approved treatments despite significantly increasing risks for heart attacks, strokes, aortic valve narrowing, and peripheral arterial disease. The promising data was presented at a major medical conference in Chicago and simultaneously published in the prestigious New England Journal of Medicine.

Advanced Clinical Progress

In the ALPACA study, participants receiving the highest tested dose of 400 milligrams saw their Lp(a) levels decrease by an average of 93.9 percent between days 60 and 180 after treatment. Those receiving 400mg doses at both the beginning and 180-day mark experienced a 94.8 percent reduction over days 30 to 360. Remarkably, levels remained 74.2 percent below baseline even after approximately 1.5 years. The drug also lowered levels of Apolipoprotein B, another cholesterol biomarker. Eli Lilly has already initiated Phase 3 trials to determine whether reducing Lp(a) actually decreases cardiovascular event risks, with patient recruitment expected to conclude this year. The company is also developing Muvalaplin, the only oral Lp(a) treatment currently in clinical trials.

Ad

Fresh Eli Lilly information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Source StockWorld